BusinessProlonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast CancerBy Nasdaq OMXDec 7, 2017, 9:05 PM UTC
BusinessTucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology (ESMO) 2017 CongressBy Nasdaq OMXSep 11, 2017, 10:00 AM UTC
BusinessCascadian Therapeutics Announces Poster Presentations on Tucatinib in Multiple Tumor Types at the European Society for Medical Oncology (ESMO) 2017 CongressBy Nasdaq OMXAug 28, 2017, 12:30 PM UTC
BusinessCascadian Therapeutics’ Lead Candidate, Tucatinib, Receives Orphan Drug Designation from FDA for Treatment of Breast Cancer Patients with Brain MetastasesBy Nasdaq OMXJun 8, 2017, 12:01 PM UTC
BusinessCascadian Therapeutics Amends HER2CLIMB Phase 2 Trial of Tucatinib in Metastatic HER2-Positive Breast Cancer to Support RegistrationBy Nasdaq OMXDec 7, 2016, 12:00 PM UTC
